SPRAVATO® Treatment

SPRAVATO® is a medication used via intra-nasal spray for the treatment of severe depression which has not fully responded to medications.

Schedule a consultation appointment to discuss if this treatment is right for you.

Frequently Asked Questions about SPRAVATO®

SPRAVATO® (esketamine) nasal spray has been approved by the FDA to be used in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression).

The team at your certified SPRAVATO® treatment center may be able to assist you in determining your specific insurance coverage for SPRAVATO® and potential out-of-pocket costs of treatment. Janssen CarePath can also help in reviewing with you and your healthcare provider your health plan benefits, insurance coverage, and out-of-pocket costs.

You and your healthcare provider will decide how long you stay on SPRAVATO® based on how you respond to it and how stable that response is. Your healthcare provider will determine the dosing frequency based on how you feel.

You’ll take SPRAVATO® twice a week for the first month. During the second month, you’ll take it once a week. After that, you’ll take it once a week or once every two weeks. You will continue to take your oral antidepressant as prescribed.

In clinical studies, improvement of depressive symptoms was demonstrated at four weeks by SPRAVATO® plus an oral antidepressant.

The observation period is a time right after you have administered SPRAVATO® when you will be allowed to rest comfortably, and during which a healthcare provider will check for any treatment side effects that you might experience. The observation period will last for at least two hours.